👤 Leila Rouhi

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
4
Articles
3
Name variants
Also published as: A Rouhi, Leili Rouhi
articles
Shahrbanoo Nandoust Kenari, Parisa Mohamadynejad, Mehdi Moghanibashi +2 more · 2025 · Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · Taylor & Francis · added 2026-04-24
Despite the current diagnostic and therapeutic methods for colorectal cancer (CRC), patients are often diagnosed at advanced stages of colorectal cancer. Recently, numerous investigations have highlig Show more
Despite the current diagnostic and therapeutic methods for colorectal cancer (CRC), patients are often diagnosed at advanced stages of colorectal cancer. Recently, numerous investigations have highlighted the role of lncRNAs in cancer development and progression. This study investigated less well-characterized genes in the colorectal cancer metastasis process. Genes expression profiles from CRC patients were downloaded from the TCGA database by the TCGAbiolinks R package. Differential gene expression analysis of miRNA, lncRNAs, and mRNAs was conducted for the M1 and M0 compared to control samples. Then, the DIANA lncbase3 tool was used to find M1-specific miRNA-LncRNA interactions. In addition, the expression of selected genes was evaluated by Real-time RT-PCR in forty-one CRC tissues. Our analysis showed that the expression levels of 77 lncRNAs, 12 miRNAs, and 627 mRNA were significantly changed only in metastatic tumors. In experimental study, significant overexpression of LncRNAs LINC00839, LINC01006, BACE1-AS and G2E3-AS1 was confirmed in metastatic tumors. Also, ROC analysis showed that these lncRNAs, especially lncRNAs G2E3-AS1 and BACE1-AS, are good prognostic biomarkers for metastatic colorectal tumors. We demonstrated that the lncRNAs G2E3-AS1 and BACE1-AS expression upregulated in CRC tissues can be good potential biomarkers for metastatic colorectal cancer. Show less
no PDF DOI: 10.1080/1354750X.2024.2448508
BACE1
Mehran Ilaghi, Zeynab Pirmoradi, Zahra Esmaili +7 more · 2025 · BMC neuroscience · BioMed Central · added 2026-04-24
Essential tremor (ET) is a common neurodegenerative disorder characterized by action tremors and various non-motor symptoms. This study investigated the potential therapeutic effects of ketamine, an N Show more
Essential tremor (ET) is a common neurodegenerative disorder characterized by action tremors and various non-motor symptoms. This study investigated the potential therapeutic effects of ketamine, an NMDA receptor antagonist with known GABA modulatory and anti-inflammatory properties, in a harmaline-induced model of ET in mice. We also evaluated the changes in expression of inflammatory interleukin 6 (IL-6) as well as Leucine rich repeat and Immunoglobin-like domain-containing protein 1 (Lingo-1), a prominent gene involved in the pathogenesis of ET. Male Swiss Webster mice were divided into four groups: control, harmaline (10 mg/kg), ketamine (8 mg/kg), and harmaline + ketamine. Tremor severity, muscle strength, locomotor activity, anxiety-like behavior, and passive avoidance learning were assessed. Cerebellar expression of Lingo-1 and IL-6 was analyzed using real-time PCR. Ketamine did not significantly reduce harmaline-induced tremors but improved muscle strength deficits in the wire grip test. In the open field test, ketamine normalized some harmaline-induced changes in locomotor activity and grooming behavior. No significant differences were observed in passive avoidance learning across groups. At the molecular level, ketamine did not mitigate the harmaline-induced increase in IL-6 expression, and Lingo-1 expression was not significantly altered by either harmaline or ketamine treatment. Our findings suggest that ketamine has limited efficacy in the harmaline ET model, showing some improvements in motor function and anxiety-like behavior but failing to address core tremor symptoms or modulate inflammatory and Lingo-1 pathways. These results highlight the complex nature of ET pathophysiology and the need for further research into targeted therapeutic approaches. Show less
📄 PDF DOI: 10.1186/s12868-025-00966-4
LINGO1
M A Mulaw, A Krause, A J Deshpande +9 more · 2012 · Leukemia · Nature · added 2026-04-24
The t(10;11)(p12;q14) is a recurring chromosomal translocation that gives rise to the CALM/AF10 fusion gene, which is found in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lympho Show more
The t(10;11)(p12;q14) is a recurring chromosomal translocation that gives rise to the CALM/AF10 fusion gene, which is found in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma. We analyzed the fusion transcripts in 20 new cases of CALM/AF10-positive leukemias, and compared the gene expression profile of 10 of these to 125 patients with other types of leukemia and 10 normal bone marrow samples. Based on gene set enrichment analyses, the CALM/AF10-positive samples showed significant upregulation of genes involved in chromatin assembly and maintenance and DNA repair process, and downregulation of angiogenesis and cell communication genes. Interestingly, we observed a striking upregulation of four genes located immediately centromeric to the break point of the t(10;11)(p12;q14) on 10p12 (COMMD3 (COMM domain containing 3), BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), DNAJC1 (DnaJ (Hsp40) homolog subfamily C member 1) and SPAG6 (sperm associated antigen 6)). We also conducted semiquantitative reverse transcriptase-PCR analysis on leukemic blasts from a murine CALM/AF10 transplantation model that does not have the translocation. Commd3, Bmi1 and Dnajc1, but not Spag6 were upregulated in these samples. These results strongly indicate that the differential regulation of these three genes is not due to the break point effect but as a consequence of the CALM/AF10 fusion gene expression, though the mechanism of regulation is not well understood. Show less
no PDF DOI: 10.1038/leu.2011.307
MLLT10
A J Deshpande, A Rouhi, Y Lin +13 more · 2011 · Leukemia · Nature · added 2026-04-24
The t(10;11)(p13-14;q14-21) translocation, giving rise to the CALM-AF10 fusion gene, is a recurrent chromosomal rearrangement observed in patients with poor prognosis acute myeloid leukemia (AML). Alt Show more
The t(10;11)(p13-14;q14-21) translocation, giving rise to the CALM-AF10 fusion gene, is a recurrent chromosomal rearrangement observed in patients with poor prognosis acute myeloid leukemia (AML). Although splicing of the CALM-AF10 fusion transcripts has been described in AML patients, the contribution of different CALM and AF10 domains to in vivo leukemogenesis remains to be defined. We therefore performed detailed structure-function studies of the CALM-AF10 fusion protein. We demonstrate that fusion of the C-terminal 248 amino acids of CALM, which include the clathrin-binding domain, to the octapeptide motif-leucine-zipper (OM-LZ) domain of AF10 generated a fusion protein (termed CALM-AF10 minimal fusion (MF)), with strikingly enhanced transformation capabilities in colony assays, providing an efficient system for the expeditious assessment of CALM-AF10-mediated transformation. Leukemias induced by the CALM-AF10 (MF) mutant recapitulated multiple aspects of full-length CALM-AF10-induced leukemia, including aberrant Hoxa cluster upregulation, a characteristic molecular lesion of CALM-AF10 leukemias. In summary, this study indicates that collaboration of the clathrin-binding and the OM-LZ domains of CALM-AF10 is sufficient to induce AML. These findings further suggest that future approaches to antagonize CALM-AF10-induced transformation should incorporate strategies, which aim at blocking these key domains. Show less
no PDF DOI: 10.1038/leu.2011.153
MLLT10